FDA approves Gilead's four-in-one HIV pill

Gilead Sciences Inc.'s four-in-one drug balm for HIV patients won Food and Drug Administration approval Monday. The pill, which Foster City-based Gilead (NASDAQ: GILD) will sell as Stribild, includes a new drug, called elvitegravir, and a new booster that allows elvitegravir to be given once a day. It also has two ingredients that the company already markets. Analysts have pegged Stribild as a potential $4 billion-a-year blockbuster.